Human immunodeficiency virus in an aging population, a complication of success

Journal of the American Geriatrics Society

Volumn 57, Issue 11, 2009, Pages 2129-2138

  Kirk, Jason B ^a,b   Goetz, Matthew Bidwell ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy; Human immunodeficiency virus; Immune activation

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CELL LOSS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; POPULATION; PREVALENCE; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE FACTORS; AGED; AGED, 80 AND OVER; AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DISEASE OUTBREAKS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES;

EID: 70350457524     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2009.02494.x     Document Type: Review

References (70)

1. Centers for Disease Control and Prevention. AIDS among persons aged > or = 50 years - United States, 1991-1996. MMWR Morb Mortal Wkly Rep 1998 47 : 21 27.
2. Anonymous. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008 372 : 293 299.
3. Ledergerber B. Epidemiology of HIV, including Response to ART, in Older Populations. 15th Conference on Retroviruses and Opportunistic Infections. 2-12-2008; Abstract 108 [on-line]. Available at Accessed April 6, 2009.
4. Medical Management of Older Patients with HIV/AIDS (R01) [on-line]. Available at Accessed November 18, 2008.
5. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: Variation by age. AIDS 2008 22 : 1463 1473.
6. Mussini C, Manzardo C, Johnson M et al. Patients presenting with AIDS in the HAART era: A collaborative cohort analysis. AIDS 2008 22 : 2461 2469.
7. Balslev U, Monforte AD, Stergiou G et al. Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients. Scand J Infect Dis 1997 29 : 337 343.
8. Valcour V, Shikuma C, Shiramizu B et al. Higher frequency of dementia in older HIV-1 individuals: The Hawaii Aging with HIV-1 Cohort. Neurology 2004 63 : 822 827.
9. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2006. HIV-AIDS Surveillance Report, 2006 (18). 2008. Atlanta, GA, Department of Health and Human Services, Centers for Disease Control and Prevention.
10. Campsmith M, Rhodes P, Hall I. Estimated Prevalence of Undiagnosed HIV Infection: US, End of 2006. 16th Conference on Retroviruses and Opportunistic Infections. 2-11-2009; Montreal, Canada. Abstract 1036 [on-line]. Available at Accessed April 6, 2009.
11. Paul SM, Martin RM, Lu SE et al. Changing trends in human immunodeficiency virus and acquired immunodeficiency syndrome in the population aged 50 and older. J Am Geriatr Soc 2007 55 : 1393 1397.
12. Linley L, Hall H, An Q et al. HIV/AIDS Diagnoses Among Persons Fifty Years and Older in 33 States, 2001-2005. National HIV Prevention Conference. 2007; Atlanta, GA. Abstract B08-1. P136-137 [on-line]. Available at Accessed April 6, 2009.
13. McDavid K, Li J, Lee LM. Racial and ethnic disparities in HIV diagnoses for women in the United States. J Acquir Immune Defic Syndr 2006 42 : 101 107.
14. Skiest DJ, Keiser P. Human immunodeficiency virus infection in patients older than 50 years. A survey of primary care physicians' beliefs, practices, and knowledge. Arch Fam Med 1997 6 : 289 294.
15. Silverberg MJ, Leyden W, Horberg MA et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007 167 : 684 691.
16. Sureka A, Parada JP, Deloria-Knoll M et al. HIV-related pneumonia care in older patients hospitalized in the early HAART era. AIDS Patient Care STDS 2004 18 : 99 107.
17. Anonymous. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000 355 : 1131 1137.
18. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004 18 : 51 58.
19. CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003 34 : 76 83.
20. Kaplan JE, Benson C, Holmes KH et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009 58 : 1 207.
21. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008 22 : 2409 2418.
22. Smith C D:A:D Study Group. Association between Modifiable and Non-modifiable Risk Factors and Specific Causes of Death in the HAART Era: The Data Collection on Adverse Events of Anti-HIV Drugs Study. 16th Conference on Retroviruses and Opportunistic Infections. 2-12-2009; Montreal, Canada. Abstract 145 [on-line]. Available at Accessed April 6, 2009.
23. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 12 : 1365 1371.
24. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol 2008 214 : 231 241.
25. Cao W, Jamieson BD, Hultin LE et al. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009 50 : 137 147.
26. Gandhi RT, Spritzler J, Chan E et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: Results from ACTG 384. J Acquir Immune Defic Syndr 2006 42 : 426 434.
27. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-infected adults and adolescents [on-line]. Available at Accessed November 4, 2008.
28. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006 166 : 1632 1641.
29. Monforte A, Abrams D, Pradier C et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008 22 : 2143 2153.
30. Janssen RS, Nwanyanwu OC, Selik RM et al. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992 42 : 1472 1476.
31. Qaseem A, Snow V, Shekelle P et al. Screening for HIV in health care settings: A guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med 2009 150 : 125 131.
32. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: Epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007 46 (Suppl 1) : S3 S8.
33. Sanders GD, Bayoumi AM, Holodniy M et al. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med 2008 148 : 889 903.
34. Owens DK, Sundaram V, Lazzeroni LC et al. Prevalence of HIV Infection Among Inpatients and Outpatients in Department of Veterans Affairs Health Care Systems: Implications for Screening Programs for HIV. Am J Public Health 2007 97 : 2173 2178.
35. Zingmond DS, Kilbourne AM, Justice AC et al. Differences in symptom expression in older HIV-positive patients: The Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr 2003 33 (Suppl 2) : S84 S92.
36. Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged>or=50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003 36 : 212 218.
37. Bhaskaran K, Hamouda O, Sannes M et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008 300 : 51 59.
38. Goetz MB, Boscardin WJ, Wiley D et al. Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS 2001 15 : 1576 1579.
39. Kaufmann GR, Furrer H, Ledergerber B et al. Characteristics, determinants, and clinical relevance of CD4T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005 41 : 361 372.
40. Haynes BF, Markert ML, Sempowski GD et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000 18 : 529 560.
41. Mocroft A, Wyatt C, Szczech L et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 2009 23 : 71 82.
42. Braithwaite RS, Roberts MS, Chang CC et al. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: A decision model. Ann Intern Med 2008 148 : 178 185.
43. Kitahata MM, Gange SJ, Abraham AG et al. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. N Engl J Med 2009 360 : 1815 1826.
44. Sabin CA, Smith CJ, Delpech V et al. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Med 2009 10 : 35 43.
45. Currier JS, Lundgren JD, Carr A et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008 118 : e29 e35.
46. Aberg JA. Cardiovascular complications in HIV management: Past, present, and future. J Acquir Immune Defic Syndr 2009 50 : 54 64.
47. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007 356 : 1723 1735.
48. Mary-Krause M, Cotte L, Gilquin J et al. Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction: A Case-Control Study Nested within FHDH ANRS CO4. 16th Conference on Retroviruses and Opportunistic Infections. 2-9-2009; Montreal, Canada. Abstract 43LB [on-line]. Available at Accessed April 6, 2009.
49. Lundgren J, Reiss P, Worm S et al. Risk of Myocardial Infarction with Exposure to Specific ARV from the PI, NNRTI, and NRTI Drug Classes: The D:A:D Study. 16th Conference on Retroviruses and Opportunistic Infections. 2-9-2009; Montreal, Canada. Abstract 44LB [on-line]. Available at Accessed April 6, 2009.
50. Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008 371 : 1417 1426.
51. Cutrell A, Brothers C, Yeo J et al. Abacavir and the potential risk of myocardial infarction. Lancet 2008 371 : 1413.
52. Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008 22 : 1389 1397.
53. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005 165 : 1179 1184. (Pubitemid 40720744)
54. De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: The D:A:D study. Diabetes Care 2008 31 : 1224 1229.
55. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005 307 : 384 387.
56. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004 18 : 137 151.
57. Winston J, Deray G, Hawkins T et al. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008 47 : 1449 1457.
58. Brown TT, Li X, Cole SR et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005 19 : 1375 1383.
59. Moore RD, Gallant JE. Renal Function after Use of Tenofovir as Part of the Initial ART Regimen. 48th Annual ICCAC/IDSA 46th Annual Meeting. 10-27-2008; Washington, DC. Abstract H-2297
60. Grulich AE, van Leeuwen MT, Falster MO et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007 370 : 59 67.
61. th Annual Meeting. 10-27-2008; Washington, DC. Abstract H-2312a [on-line]. Available at Accessed April 6, 2009.
62. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 2006 20 : 2165 2174.
63. Triant VA, Brown TT, Lee H et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008 93 : 3499 3504.
64. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. HIV-AIDS Surveillance Report, 2007 (18), 1-63. 2009. Atlanta, GA, Department of Health and Human Services, Centers for Disease Control and Prevention.
65. Crothers K, Butt AA, Gibert CL et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006 130 : 1326 1333.
66. Desquilbet L, Jacobson LP, Fried LP et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007 62A : 1279 1286.
67. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001 56A : M146 M156.
68. Mocroft A, Reiss P, Gasiorowski J et al. Serious Fatal and Non-fatal Non-AIDS-defining Illnesses in Europe. 16th Conference on Retroviruses and Opportunistic Infections. 2-9-2009; Montreal, Canada. Abstract 707 [on-line]. Available at Accessed April 6, 2009.
69. Effros RB, Fletcher CV, Gebo K et al. Aging and infectious diseases: Workshop on HIV infection and aging: What is known and future research directions. Clin Infect Dis 2008 47 : 542 553.
70. Branson BM, Handsfield HH, Lampe MA et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006 55 : 1 17.